ATNM · Company research
Actinium Pharmaceuticals, Inc (ATNM): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
18records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| A doctor with more than 20 years in biopharma leadership and finance will lead Actinium's finances. - Stock Titan | A doctor with more than 20 years in biopharma leadership and finance will lead Actinium's finances. Stock Titan | View source ↗ | Stock Titan | Oct 15, 2026 | neutral | 0 | 0.6 |
| Actinium Pharmaceuticals (ATNM) Edges Higher to $1.10 as Shares Hold Above Key Support - Fibonacci Time Zone - https://www.dars.gov.et/ | Actinium Pharmaceuticals (ATNM) Edges Higher to $1.10 as Shares Hold Above Key Support - Fibonacci Time Zone https://www.dars.gov.et/ | View source ↗ | https://www.dars.gov.et/ | Oct 10, 2026 | neutral | 0 | 0.6 |
| Next Generation Antibody Therapeutics Market, 2nd Edition: Global Industry Trends and Forecast to 2035 | Immunocytokines and Combination Therapies Drive Growth | The global next generation antibody therapeutics market is projected to grow from USD 5.45 billion to USD 5.76 billion by 2035, with a modest 1% CAGR. Growth is driven by advances in biotechnology, targeted treatments, and expanding clinical pipelines for cancer, rare diseases, and cardiovascular conditions. Immunocytokines and combination therapies are expected to demonstrate the strongest growth potential, while North America is projected to maintain approximately 64% market share. | View source ↗ | GlobeNewswire Inc. | Oct 9, 2026 | bullish | 1 | 1 |
| Next Generation Antibody Therapeutics Market, 2nd Edition: Global Industry Trends and Forecast to 2035 | Immunocytokines and Combination Therapies Drive Growth | The global next generation antibody therapeutics market is projected to grow from USD 5.45 billion to USD 5.76 billion by 2035, with a modest 1% CAGR. Growth is driven by advances in biotechnology, targeted treatments, and expanding clinical pipelines for cancer, rare diseases, and cardiovascular conditions. Immunocytokines and combination therapies are expected to demonstrate the strongest growth potential, while North America is projected to maintain approximately 64% market share. | View source ↗ | GlobeNewswire Inc. | Oct 9, 2026 | bullish | 1 | 1 |
| (AMEX: ATNM) Share Price, ATNM Stock News, ATNM Share Price & Updates - Kalkine | (AMEX: ATNM) Share Price, ATNM Stock News, ATNM Share Price & Updates Kalkine | View source ↗ | Kalkine | Sep 30, 2026 | neutral | 0 | 0.6 |
| Actinium Pharmaceuticals (ATNM) Slips 3.28% to $1.18 as Shares Test Mid-Range Support - Double EMA - dars.gov.et | Actinium Pharmaceuticals (ATNM) Slips 3.28% to $1.18 as Shares Test Mid-Range Support - Double EMA dars.gov.et | View source ↗ | dars.gov.et | Sep 21, 2026 | neutral | 0 | 0.6 |
| Actinium Pharmaceuticals (ATNM) grants director new stock awards - Stock Titan | Actinium Pharmaceuticals (ATNM) grants director new stock awards Stock Titan | View source ↗ | Stock Titan | Sep 4, 2026 | neutral | 0 | 0.6 |
| Actinium Pharmaceuticals (ATNM) grants director $1.00 options and RSUs - Stock Titan | Actinium Pharmaceuticals (ATNM) grants director $1.00 options and RSUs Stock Titan | View source ↗ | Stock Titan | Sep 4, 2026 | neutral | 0 | 0.6 |
| Actinium (ATNM) Update: Slides 1.79% to $1.10 in Latest Trading; Next Test: Traders Can Monitor the $1.04-$1.16 Range in the Latest Session - Advance Decline Line - dars.gov.et | Actinium (ATNM) Update: Slides 1.79% to $1.10 in Latest Trading; Next Test: Traders Can Monitor the $1.04-$1.16 Range in the Latest Session - Advance Decline Line dars.gov.et | View source ↗ | dars.gov.et | Aug 23, 2026 | neutral | 0 | 0.6 |
| Actinium Adds Two U.S. Patents, Expands Actimab-A Manufacturing - Stock Titan | Actinium Adds Two U.S. Patents, Expands Actimab-A Manufacturing Stock Titan | View source ↗ | Stock Titan | Aug 14, 2026 | neutral | 0 | 0.6 |
| Actinium Pharmaceuticals Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView | Actinium Pharmaceuticals Disclosed Failure to Satisfy a Continued Listing Rule or Standard TradingView | View source ↗ | TradingView | Aug 14, 2026 | neutral | 0 | 0.6 |
| Actinium Pharmaceuticals (ATNM) Dips 2.9% as Biotech Stock Nears Support Zone - Percent Below MA - dars.gov.et | Actinium Pharmaceuticals (ATNM) Dips 2.9% as Biotech Stock Nears Support Zone - Percent Below MA dars.gov.et | View source ↗ | dars.gov.et | Jul 16, 2026 | neutral | 0 | 0.6 |
| SLS Vs ATNM: Which Cancer Stock Has Bigger Upside Ahead Of Fresh Data Reveal? - Stocktwits | SLS Vs ATNM: Which Cancer Stock Has Bigger Upside Ahead Of Fresh Data Reveal? Stocktwits | View source ↗ | Stocktwits | Apr 20, 2026 | neutral | 0 | 0.6 |
| ATNM Should I Buy - Intellectia AI | ATNM Should I Buy Intellectia AI | View source ↗ | Intellectia AI | Feb 14, 2026 | neutral | 0 | 0.6 |
| Why Is Actinium Pharmaceuticals Stock Rising Today? - Stocktwits | Why Is Actinium Pharmaceuticals Stock Rising Today? Stocktwits | View source ↗ | Stocktwits | Dec 11, 2025 | neutral | 0 | 0.6 |
| symbol__ Stock Quote Price and Forecast - CNN | symbol__ Stock Quote Price and Forecast CNN | View source ↗ | CNN | Mar 26, 2024 | neutral | 0 | 0.6 |
| Actinium shares surge on promising data for AML radiotherapy candidate (NYSE:ATNM) - Seeking Alpha | Actinium shares surge on promising data for AML radiotherapy candidate (NYSE:ATNM) Seeking Alpha | View source ↗ | Seeking Alpha | Feb 27, 2024 | neutral | 0 | 0.6 |
| Actinium Pharmaceuticals, Inc. (ATNM) Stock Price, News, Quote & History - Yahoo! Finance Canada | Actinium Pharmaceuticals, Inc. (ATNM) Stock Price, News, Quote & History Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | May 16, 2017 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.